167 related articles for article (PubMed ID: 37860016)
1. Oncolytic virotherapy targeting the IL15 pathway.
Yoo SY; Heo J
Mol Ther Oncolytics; 2023 Dec; 31():100732. PubMed ID: 37860016
[No Abstract] [Full Text] [Related]
2. Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation.
He T; Hao Z; Lin M; Xin Z; Chen Y; Ouyang W; Yang Q; Chen X; Zhou H; Zhang W; Wu P; Xu F
Oncoimmunology; 2022; 11(1):2093054. PubMed ID: 35800155
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
4. Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy.
Du YN; Wei Q; Zhao LJ; Fan CQ; Guo LR; Ye JF; Li Y
Biomed Pharmacother; 2022 Jul; 151():113110. PubMed ID: 35605298
[TBL] [Abstract][Full Text] [Related]
5.
Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
Front Immunol; 2021; 12():610042. PubMed ID: 33679747
[TBL] [Abstract][Full Text] [Related]
6. Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.
Lv P; Liu X; Chen X; Liu C; Zhang Y; Chu C; Wang J; Wang X; Chen X; Liu G
Nano Lett; 2019 May; 19(5):2993-3001. PubMed ID: 30964695
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus.
Yan Y; Xu H; Wang J; Wu X; Wen W; Liang Y; Wang L; Liu F; Du X
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31278126
[TBL] [Abstract][Full Text] [Related]
8. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
Ye JF; Qi WX; Liu MY; Li Y
Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model.
Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D
Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750
[TBL] [Abstract][Full Text] [Related]
10. Delivery and Biosafety of Oncolytic Virotherapy.
Li L; Liu S; Han D; Tang B; Ma J
Front Oncol; 2020; 10():475. PubMed ID: 32373515
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective.
Ebrahimi S; Ghorbani E; Shafiee M; Ryzhikov M; Hassanian SM; Azadmanesh K
J Cell Biochem; 2019 Mar; 120(3):2801-2809. PubMed ID: 30260014
[TBL] [Abstract][Full Text] [Related]
12. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma.
Wilkinson MJ; Smith HG; Pencavel TD; Mansfield DC; Kyula-Currie J; Khan AA; McEntee G; Roulstone V; Hayes AJ; Harrington KJ
Int J Cancer; 2016 Sep; 139(6):1414-22. PubMed ID: 27116656
[TBL] [Abstract][Full Text] [Related]
14. Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?
Dey M; Auffinger B; Lesniak MS; Ahmed AU
Future Virol; 2013 Jul; 8(7):675-693. PubMed ID: 24910708
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer and oncolytic virotherapy--enemy's enemy.
Li Z; Feiyue Z; Gaofeng L; Haifeng L
Transl Oncol; 2023 Jan; 27():101563. PubMed ID: 36244134
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?
Soldozy S; Mulligan KM; Zheng DX; Levoska MA; Cullison CR; Elarjani T; Eichberg DG; Ampie LE; Shah AH; Yağmurlu K; Shaffrey ME; Scott JF; Komotar RJ
Brain Sci; 2021 Sep; 11(10):. PubMed ID: 34679325
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
18. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
19. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model.
Senekal NS; Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
Bull Math Biol; 2021 May; 83(7):75. PubMed ID: 34008149
[TBL] [Abstract][Full Text] [Related]
20. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
